Immunopharmacologic Monitoring of Therapeutic Serum Antibodies (Therapeutic Drug Monitoring for Biologic Therapies)
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage policy for measurement of serum drug levels and anti‑drug antibodies primarily for inflammatory bowel disease (IBD) and states noncoverage for most other indications; applies to outpatient testing. Affects clinicians ordering TDM and laboratories performing assays.
No material clinical or coverage changes in this revision.
Coverage Criteria for Therapeutic Drug and Anti-Drug Antibody Monitoring
Anti-TNF TDM in IBD
Covered when ALL of the following are met for individuals with inflammatory bowel disease:
Uses OR within the listed specific timepoint conditions
Vedolizumab/Ustekinumab TDM in IBD
Covered when ANY of the following are met for individuals with IBD on vedolizumab or ustekinumab:
Two alternative covered scenarios
Not Medically Necessary / Not Covered
Not covered when any of the following apply:
Explicit noncoverage
Explicit list of agents
Anti-TNF: Indications for testing
Consensus recommendations for applying TDM in IBD
Consensus strong for anti-TNFs (items 1-4)
Vedolizumab and Ustekinumab: Indications
Agent-specific appropriateness varies for non-anti-TNF biologics
items 5-8
items 9-12
Drug-specific thresholds and interpretation
Drug concentration thresholds and interpretation guidance
items 13-16
items 17-21
items 22-23
items 24-27
Agent-specific monitoring thresholds
Covered when meeting agent-specific monitoring targets or documented rationale:
source provides target trough for remission
two timepoint thresholds provided
no quantitative targets recommended
Measurement of serum drug levels and/or antibodies to the listed biologic agents in an outpatient setting for any reason other than the covered inflammatory bowel disease (IBD) indications does not meet coverage criteria. The enumerated agents include adalimumab, certolizumab, etanercept, golimumab, infliximab (and biosimilars), rituximab, ustekinumab, and vedolizumab, and testing for these drugs outside the specified IBD scenarios may be denied.
The National Institute for Health and Care Excellence (NICE) concluded that enzyme‑linked immunosorbent assay (ELISA) kits “show promise” for therapeutic monitoring of TNF‑alpha inhibitors in Crohn’s disease but that there is insufficient evidence to recommend their routine adoption. NICE therefore recommends ELISA testing be performed in the context of research or data collection rather than as routine clinical practice.
For vedolizumab and ustekinumab, available evidence is insufficient to define specific quantitative induction or maintenance concentration targets. Guidance supports only confirming that the drug is detectable; no numeric trough or induction targets are recommended for routine use.
Drug and/or antibody concentration testing for anti‑TNF therapies performed for individuals without inflammatory bowel disease (for example, those with rheumatoid arthritis, psoriatic arthritis, psoriasis, or spondyloarthritis) does not meet coverage criteria and is considered not medically necessary.
Major guideline bodies advise against routine proactive therapeutic drug monitoring (TDM) for all unselected patients in remission. The American Gastroenterological Association (AGA) recommends a reactive TDM approach for adults with active IBD and makes no recommendation for routine proactive TDM in quiescent disease; the American College of Gastroenterology (ACG) likewise notes insufficient evidence to support proactive routine monitoring in all patients in remission, particularly ulcerative colitis.
Coding, Thresholds, and Referenced Values
| not listed | Document references proprietary assay offerings (OptimAbs, Prometheus Anser, DoseASSURE) but does not provide CPT/HCPCS codes. |
Provider Actions, Documentation, and Prior Authorization
Limit coverage to specified IBD scenarios
Coverage is allowed for therapeutic drug and/or anti-drug antibody concentration testing for anti‑TNF agents in individuals with inflammatory bowel disease when performed at the end of induction for all anti‑TNFs, at least once during maintenance therapy, at the end of induction in primary non‑responders, or in patients with confirmed secondary loss of response. For vedolizumab or ustekinumab, coverage is limited to non‑responders at the end of induction or patients with confirmed secondary loss of response (testing for these agents otherwise lacks sufficient data for quantitative targets).
- Anti‑TNF covered timepoints: end of induction; at least once during maintenance; end of induction in primary non‑responders; confirmed secondary loss of response. [[source cited]]
- Vedolizumab/ustekinumab covered only for non‑responders at end of induction or confirmed secondary loss of response; no quantitative induction/maintenance targets beyond detectable drug. [[source cited]]
Potential prior authorization for routine/proactive testing
Prior authorization may be required when ordering ELISA‑based therapeutic monitoring tests used routinely or when testing outside guideline‑supported scenarios; NICE recommends ELISA tests be used within research or data collection rather than routine adoption, which may trigger authorization requirements or denials for routine/proactive use.
- NICE: ELISA kits show promise but insufficient evidence to recommend routine adoption—use in research/data collection. [[source cited]]
- ACG/AGA guidance limits proactive routine TDM in quiescent patients; testing outside these contexts may prompt prior authorization. [[source cited]]
Document concentration thresholds to justify monitoring
When ordering or justifying therapeutic drug monitoring, use the policy's agent‑specific concentration thresholds (e.g., certolizumab week‑6 >32 μg/mL and maintenance trough 15 μg/mL; golimumab week‑6 ≥2.5 μg/mL and maintenance >1 μg/mL) and the guidance that vedolizumab/ustekinumab require only confirmation of detectable drug.
- Certolizumab: week 6 >32 μg/mL; maintenance trough for remission = 15 μg/mL. [[source cited]]
- Golimumab: week 6 ≥2.5 μg/mL; maintenance trough for remission >1 μg/mL. [[source cited]]
- Vedolizumab/ustekinumab: data insufficient for quantitative targets—confirm detectable drug only. [[source cited]]
Use TDM to inform treatment changes (intensify vs switch)
Use therapeutic drug monitoring results to inform treatment changes per described algorithms—results may guide decisions such as dose intensification, switching biologic class, or other escalation strategies when TDM indicates low drug levels or high anti‑drug antibodies.
- Algorithms in the literature used combined drug and antibody measurements to direct whether to intensify dose or switch therapy and showed similar disease control with lower costs when guided by TDM. [[source cited]]
- Studies report that appropriate changes in management based on TDM results were associated with trends toward increased remission. [[source cited]]
Prefer reactive‑first TDM per AGA
Follow a reactive‑first approach consistent with AGA guidance: perform reactive TDM to guide treatment changes in adults with active IBD; do not rely on routine proactive TDM in quiescent patients where AGA makes no recommendation for routine proactive monitoring.
- AGA: suggests reactive TDM to guide treatment changes in adults with active IBD (conditional recommendation, very low quality evidence). [[source cited]]
- AGA: makes no recommendation for routine proactive TDM in patients with quiescent IBD. [[source cited]]
Evidence exists for proactive TDM but does not mandate routine use
Be aware of evidence for proactive TDM: randomized and observational studies comparing proactive TDM versus standard care or dose intensification are referenced and may inform provider decisions, but they do not mandate routine proactive monitoring across all patients.
- Papamichael et al. (2019) reported better long‑term outcomes with proactive adalimumab TDM vs standard care. [[source cited]]
- Syversen et al. (2021) and other trials compare TDM‑guided vs standard therapy and inform the evidence base for proactive monitoring. [[source cited]]
Required indication and timing documentation
When requesting coverage, document the indication and timing for the test—support testing at the indicated timepoints such as end of induction, at least once during maintenance, end of induction for primary non‑responders, or for confirmed secondary loss of response; for vedolizumab/ustekinumab document non‑response at end of induction or confirmed secondary loss of response.
- State the clinical scenario prompting testing (end of induction, maintenance monitoring, primary non‑response, confirmed secondary loss of response). [[source cited]]
- For vedolizumab/ustekinumab, document non‑response at end of induction or confirmed secondary loss of response to justify testing. [[source cited]]
Document indication and thresholds used
Include in the record the specific indication and the drug concentration threshold being used to justify testing and clinical decisions (e.g., minimal infliximab trough >3 μg/mL post‑induction; adalimumab week‑4 ≥5 μg/mL; certolizumab and golimumab thresholds as specified).
- Infliximab post‑induction minimal trough >3 μg/mL (week 14); >7 μg/mL associated with mucosal healing. [[source cited]]
- Adalimumab week 4 minimum ≥5 μg/mL; maintenance trough >5 μg/mL in remission. [[source cited]]
- Certolizumab: week 6 >32 μg/mL; maintenance trough 15 μg/mL. [[source cited]]
- Golimumab: week 6 ≥2.5 μg/mL; maintenance trough >1 μg/mL. [[source cited]]
Ensure LDT validation and CLIA compliance
If using laboratory‑developed tests (LDTs), ensure the laboratory has validated the assay and performs it in‑house under CLIA as high‑complexity testing; LDTs are not FDA‑cleared/approved and must be validated by the performing lab.
- LDTs are regulated by CMS under CLIA as high‑complexity tests and must be validated and performed in the laboratory. [[source cited]]
- FDA clearance/approval is not required for clinical use of LDTs but does not substitute for CLIA validation. [[source cited]]
Use TDM to inform and document treatment changes
Use TDM results to inform treatment modifications: low drug concentrations without antibodies may support dose intensification, whereas low drug concentrations with detectable high‑titer antibodies often prompt switching therapy; document how TDM informed the chosen management step.
- Steenholdt et al. and Mitchell et al. describe algorithms where combined drug and antibody measurements guide whether to intensify dosing or switch biologics. [[source cited]]
- Infliximab guidance: absence of detectable drug with high‑titer anti‑infliximab antibodies requires therapy change; low‑level antibodies can sometimes be overcome. [[source cited]]
Denial risk: non‑IBD indications
Requests for drug and/or antibody concentration testing for anti‑TNF therapies in individuals without inflammatory bowel disease (including spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) will be denied as not meeting coverage criteria.
- Testing outside IBD (including listed rheumatologic and dermatologic conditions) does not meet coverage criteria and may be denied. [[source cited]]
Denial risk: specified drugs/outpatient testing
Measurement of serum drug levels and/or antibodies for the listed biologics (adalimumab, certolizumab, etanercept, golimumab, infliximab and listed biosimilars, rituximab, ustekinumab, vedolizumab) in an outpatient setting for reasons other than the covered IBD indications does not meet coverage criteria and may be denied.
- The policy explicitly lists agents for which outpatient measurement for non‑covered reasons does not meet criteria. [[source cited]]
NICE guidance may limit routine adoption of ELISA TDM
NICE guidance notes that ELISA kits show promise but there is insufficient evidence to recommend routine adoption; therefore routine use of ELISA‑based TDM outside research or data collection could be limited or denied.
- NICE (2016): ELISA kits show promise for therapeutic monitoring in Crohn's disease but insufficient evidence to recommend routine adoption—use in research/data collection recommended. [[source cited]]
Background and Scope
Anti‑drug antibodies can reduce the efficacy of biologic therapies and increase the likelihood of adverse outcomes, particularly with tumor necrosis factor (TNF) inhibitors. Therapeutic drug monitoring — measurement of drug trough concentrations and anti‑drug antibodies — is used to help explain primary nonresponse or secondary loss of response and to guide decisions such as dose intensification, switching agents, or confirming pharmacokinetic versus pharmacodynamic failure.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.